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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comantithrombotic regimen was maintained throughout the whole study period (median 2
years). The primary end point was deﬁned as net clinical outcomes, a composite of
major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity
score-matching analysis was also performed in 99 patient pairs.
Results: The net clinical outcomes of the TAT group was worse than the DAPT group
(34.3% v 21.1%, p¼0.006), which was mainly driven by higher incidence of major
bleeding (16.7% vs 4.6%, p< 0.001), without any signiﬁcant increase in MACCE
(22.1% vs 17.7%, p¼0.313). In multivariate analysis, the TAT was an independent
predictor for worse net clinical outcomes (HR 1.67; 95% CI 1.09-2.57; p¼0.018) and
major bleeding (HR 3.74; 95% CI 1.74-8.02; p¼0.001). After propensity score-
matching, TAT group still had worse net clinical outcomes, mainly driven by higher
major bleeding, than DAPT group.
Conclusions: In AF patients undergoing DES implantation, prolonged administration
of TAT is associated with worse net clinical outcomes due to the substantial increase
in major bleeding without any improvement of MACCE.
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Background: Chronic kidney disease (CKD) confers increased risk for bleeding
and ischemic complications after percutaneous coronary intervention (PCI).
Guidelines recommend dual antiplatelet therapy (DAPT) in patients undergoing PCI
and anticoagulation in patients with atrial ﬁbrillation (AF) and CHADS2 scores2.
The optimal antithrombotic therapy in patients with CKD and AF after PCI is
unknown.
Methods: The AVIATOR (Antithrombotic strategy Variability In ATrial ﬁbrillation
and Obstructive coronary disease Revascularized with PCI) registry, included 859
consecutive patients with AF treated with PCI, of whom 286 had CKD (e-GFR< 60
ml/min).CKD patients were stratiﬁed in 2 groups; triple therapy (TT; warfarin plus
DAPT) or DAPT (aspirin plus clopidogrel. Major adverse cardiovascular events
(MACE) and clinically relevant bleeding (BARC2) were compared between the
groups at one year.
Results: Mean age was similar in the 2 groups (769 years). Patients receiving
TT (n¼127, 44.4%) were more often male and had higher ejection fraction
compared to patients discharged on DAPT (n¼159, 55.6%). Mean CHADS2
scores were identical between groups (3.11). MACE incidence at 1-year was
similar in the TT vs. DAPT groups (20 vs. 11%, p¼0.54) but patients on TT
tended to bleed more often (15 vs. 7%, p¼0.04). However, after adjusting for
confounding factors the association of TT with increased bleeding was attenu-
ated. (Figure)Conclusions: The most commonly prescribed regimen in these high risk patients with
CKD and AF undergoing PCI is DAPT. Patients on TT had similar rates of 1-year
MACE but more bleeding compared to those given DAPT.B140 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT AbstTCT-477
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Background: Elderly patients with atrial ﬁbrillation (AF) undergoing percutaneous
coronary intervention (PCI) are at an increased risk for bleeding and ischemic com-
plications. Optimum antithrombotic therapy in this group is controversial and
challenging.
Methods: Among 859 patients from the AVIATOR (Antithrombotic strategy vari-
ability in AF and obstructive coronary disease) registry who underwent PCI, 387
patients with age  75 were selected for this analysis. At discharge, these patients
were stratiﬁed into two groups: those receiving dual antiplatelet therapy (DAPT;
aspirin plus clopidogrel), and those receiving triple therapy (TT; DAPT plus warfarin).
Major adverse cardiovascular events (MACE) and bleeding rates in these antith-
rombotic groups were studied after one year.
Results: The mean age of patients who received DAPT was 814 years, whereas
those on TT had a mean age of 803 years. Patients receiving DAPT (n¼203, 52.5%)
were more likely to have a history of bleeding and infarction, while those on TT
(n¼184, 47.5%) had a past history of stroke. The 1-year MACE (15.7% vs 12.2%, HR
0.82, p¼0.548, for DAPT vs TT, respectively) and bleeding (9.4% vs 12.1%, HR
1.25, p¼0.413, for DAPT vs TT, respectively) rates were similar between the two
groups.
Conclusions: In contrast to consensus statements, elderly patients with AF under-
going PCI are most frequently treated with DAPT. Bleeding and ischemic compli-
cations remain substantial in this cohort irrespective of treatment.TCT-478
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Background: Development of deep venous thrombosis (DVT) in the setting of cancer
portends a poor prognosis. Low molecular weight heparins ( LMWH) are considered
the standard of care due to their superiority over warfarin. Additionally warfarin
resistance is common in cancer patients. The subcutaneous administration of LMWH
on a chronic basis is cumbersome and inconvenient. New oral anticoagulants (NOAC)
are promising drugs which can simplify long term care of cancer patients with DVT.
However little is known on their efﬁcacy in this setting. We therefore sought to
evaluate the role of NOAC in patients with cancer- related lower extremity (LE) DVT
who received rivaroxaban and apixaban following percutaneous endovenous inter-
vention (PEVI).
Methods: PEVI was performed in 50 patients with cancer who had developed
extensive symptomatic LE DVT. It was bilateral in 18 patients (36%). At the time of
DVT, 15 patients (30%) were on warfarin of whom 7 had therapeutic INR (64%).
PEVI was performed within 235 hours of admission. All patients received heparin
which was stopped after completion of PEVI. Rivaroxaban was initiated at 20 mg
daily and apixaban at 5 mg twice daily, 2 hours after PEVI, and continued indeﬁnitely.
Warfarin was stopped in all. The mean follow up was 154 months. The patients were
evaluated for mortality, recurrent VTE and bleeding during this period.racts/Pharmacotherapy - Chronic anticoagulants (warfarin and newer agents)
